Keywords: eli, lilly, solvay, sustained-release, moxonidine, crashes, phase
Eli Lilly and Solvay's sustained-release moxonidine crashes in Phase III
Article | 09 September 1999
Eli Lilly has terminated the development of a sustained-releaseformulation of its selective imidazoline receptor antagonist, moxonidine, following negative trial data ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
